Blog

NEW CANAAN, CT / ACCESS Newswire / June 30, 2025 / Network-1 Technologies, Inc. (NYSE:NTIP) announced today that it has initiated patent litigation against Samsung Electronics Co., LTD and Samsung Electronics America, Inc. (collectively, “Samsung”) in the United States District Court for the Eastern District of Texas for infringement of U.S. Patent No. 11,233,780, U.S. Patent No. 11.916,893, U.S. Patent No. 12,207,094, U.S. Patent No. 12,166,869, U.S. Patent No.11,606,204, and U.S. Patent No. 11.973,864 (collectively, the “Patents-in-Suit”).

The lawsuit alleges that Samsung infringes the Patents-in-Suit by supporting certain eSIM (embedded Subscriber Identification Module) and 5G technologies in its mobile devices, including its Galaxy smartphones, watches and tablets (the “Accused Products”). The Accused Products operate consistent with certain GSMA and ETSI industry standards.

The Patents-in-Suit are part of the M2M/IoT patent portfolio acquired by Network-1 in December 2017 (the “M2M/IoT Patent Portfolio”). The M2M/IoT Patent Portfolio relates to, among other things, enabling technology for authenticating and using eSIM technology in Internet of Things (“IoT”), Machine-to-Machine, and other mobile devices, including smartphones, tablets, watches, computers and automobiles. Patents in the M2M/IoT Patent Portfolio also relate to enabling technologies for 5G network authentication used in consumer and M2M devices (including smartphones), and the latest available Internet transport layer security solutions.

A study by the Trusted Connectivity Alliance (TCA) found that 2024 was a landmark year of growth across the global eSIM ecosystem during which the volume of eSIM device shipments surpassed 500 million units with eSIM profile downloads increasing by 56%.

Network-1’s M2M/IoT Patent Portfolio includes forty-one (41) issued U.S. patents (and 6 pending applications), plus fifteen (15) issued non-U.S. patents. The patent terms of the MTM/IoT Patent Portfolio are currently expected to extend until 2033-2034. Network-1 has been developing the portfolio since its acquisition and anticipates further issuances of additional claims.

The M2M/IoT Patent Portfolio is available for licensing to firms that make use of the technologies covered by its patents, including eSIM and 5G technologies covered by the relevant GSMA and ETSI standards, as implemented in Internet of Things and M2M products as well as devices utilizing 5G.

ABOUT NETWORK-1 TECHNOLOGIES, INC.

Network-1 Technologies, Inc. is engaged in the acquisition, development, licensing and protection of its intellectual property and proprietary technologies. Network-1 works with inventors and patent owners to assist in the development and monetization of their patented technologies. Network-1 currently owns one hundred fourteen (114) U.S. patents and sixteen (16) international patents covering various technologies, including enabling technology for authenticating and using eSIM technology in Internet of Things (“IoT”), certain advanced technologies related to high frequency trading, technologies relating to document stream operating systems and the identification of media content and enabling technology to support, among other things, the interoperability of smart home IT devices. Network-1’s current strategy includes efforts to monetize four patent portfolios (the M2M/IoT, HFT, Cox and Smart Home portfolios). Network-1’s strategy is to focus on acquiring and investing in high quality patents which management believes have the potential to generate significant licensing opportunities as Network-1 has achieved with respect to its Remote Power Patent and Mirror Worlds Patent Portfolio. Network-1’s Remote Power Patent has generated licensing revenue in excess of $188,000,000 from May 2007 through March 31, 2025. Network-1 has achieved licensing and other revenue of $47,150,000 through March 31, 2025 with respect to its Mirror Worlds Patent Portfolio.

This release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These statements address future events and conditions concerning Network-1’s business plans. Such statements are subject to a number of risk factors and uncertainties as disclosed in the Network-1’s Annual Report on Form 10-K for the year ended December 31, 2024 filed with the Securities and Exchange Commission on February 28, 2025 and its Quarterly Report on Form 10-Q for the three months ended March 31, 2025 including, among others, Network-1’s uncertain revenue from licensing its intellectual property, uncertainty as to the outcome of pending litigation involving Network-1’s HFT Patent Portfolio, whether Network-1 will be successful in its appeal to the Federal Circuit of the District Court judgment of non-infringement dismissing Network-1’s litigation against Google and YouTube involving certain patents within our Cox Patent Portfolio, the ability of Network-1 to successfully execute its strategy to acquire or make investments in high quality patents with significant licensing opportunities, Network-1’s ability to achieve revenue and profits from its Cox Patent Portfolio, M2M/IoT Patent Portfolio, HFT Patent Portfolio and Smart Home Portfolio, as well as a successful outcome on its investment in ILiAD Biotechnologies, LLC or other intellectual property it may acquire or finance in the future, the ability of Network-1 to enter into additional license agreements, uncertainty as to whether cash dividends will continue be paid, Network-1’s ability to enter into strategic relationships with third parties to license or otherwise monetize their intellectual property, , the risk in the future of Network-1 being classified as a Personal Holding Company which may result in Network-1 issuing a special cash dividend to its stockholders, future economic conditions and technology changes and legislative, regulatory and competitive developments. Except as otherwise required to be disclosed in periodic reports, Network-1 expressly disclaims any future obligation or undertaking to update or revise any forward-looking statement contained herein.

Corey M. Horowitz, Chairman and CEO
Network-1 Technologies, Inc.
917-692-0000

SOURCE: Network-1 Technologies, Inc.

View the original press release on ACCESS Newswire

PLANO, TX / ACCESS Newswire / June 30, 2025 / Think Power Solutions, a leading provider of tech-enabled utility infrastructure and field services, announces a key leadership transition as Daniel Helman assumes the role of Chief Executive Officer, effective immediately. This follows the departure of Founder and CEO Hari Vasudevan, whose 12 years of visionary leadership have helped shape the company into a trusted partner across the electric utilities industry.

Hari Vasudevan remains an active investor in Think Power Solutions, continuing to support the company’s long-term mission.

Daniel Helman brings more than 35 years of operational experience to the role, including 20 years in the power generation and construction industry. Most recently, Dan served as Chief Operating Officer of Think Power Solutions for two years, preceded by his tenure as Environmental, Health, and Safety Leader. His deep operational expertise, unwavering commitment to safety, and passion for innovation make him exceptionally well-suited to lead Think Power into its next phase of growth.

“I’m honored to lead this outstanding team into the next chapter,” said Daniel Helman. “We’ll continue to build on the strong foundation Hari created and drive new levels of operational excellence and client success.”

Dan’s appointment signals continued momentum toward excellence, innovation, and customer-centric service delivery. Under his leadership, Think Power Solutions will remain focused on delivering exceptional value, safety, and performance across its client portfolio.

“We are excited to welcome Dan as our new CEO,” said Lawrence LeBlanc, Chief Financial Officer at Think Power Solutions. “His proven leadership, operational discipline, and alignment with our values position him to guide the company into a dynamic and impactful future.”

To learn more about Dan Helman, visit his LinkedIn.

About Think Power Solutions
Think Power Solutions is a leading provider of AI-enabled utility infrastructure solutions. The company partners with many of the nation’s largest investor-owned and cooperative utilities. Known for its operational excellence, innovative technology, and industry-leading safety record, Think Power has earned a reputation as a trusted partner in the utility sector. With a culture grounded in innovation, excellence, strong employee engagement, and entrepreneurial spirit, Think Power Solutions continues to attract top-tier talent and deliver high-performance services and products that support the evolving needs of the utility industry.

For more information visit: https://www.thinkpowersolutions.com Follow us on LinkedIn, X, and Facebook.

Sayantan Dasgupta
Director Marketing – Brand & Content
Think Power Solutions
sayantan.dasgupta@thinkpowersolutions.com

SOURCE: Think Power Solutions

View the original press release on ACCESS Newswire

– Conducts 27% Workforce Reduction, Ceases Operations at Applied DNA Clinical Labs, Positions LineaRx for Growth –

STONY BROOK, NY / ACCESS Newswire / June 30, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN), a leader in PCR-based DNA technologies, announced a strategic restructuring and realignment of resources to focus exclusively on its synthetic DNA manufacturing business, LineaRx. As part of actions undertaken, the Company implemented a workforce reduction of approximately 27% of headcount and has ceased operations at Applied DNA Clinical Labs (ADCL), a business that provides molecular and genetic testing services, effective June 27, 2025.

The Company’s actions are intended to substantially reduce its operating costs and concentrate resources behind LineaRx to: (i) enhance the capabilities of LineaRx’s LineaDNA™ and LineaIVT™ platforms while scaling commercial adoption, (ii) expand its service offerings; and (iii) pursue strategic partnerships. LineaRx is advancing platform technologies for the enzymatic manufacture of synthetic DNA and associated enzymes used in the production of DNA- and RNA-based medicines.

“We believe these strategic decisions enable us to set business priorities, funds, and management attention behind LineaRx as our highest-conviction growth opportunity, while also positioning the company for greater operational efficiency, sharper execution, and clearer industry and investment theses,” stated Judy Murrah, chairperson, president, and CEO.

Added Clay Shorrock, president of LineaRx, “Demand for enzymatically produced DNA is accelerating, driven by the expanding field of genetic medicines. Our LineaDNA and LineaIVT platforms are well-positioned to meet this need, and we are aligning all resources towards customer acquisition, expanding market penetration, and scaling efficiently.”

Corporate Updates

• The workforce reduction represents an approximately 27% reduction in headcount, equating to a projected 23% reduction in annual payroll costs, excluding payroll expenses incurred as a result of the previously announced retirement of the Company’s former Chairman and CEO. The projected annual payroll savings is expected to be partially offset by approximately $300 thousand in one-time charges related to the workforce reduction, primarily for separation benefits.

• The Company expects to incur the majority of workforce reduction-related costs by the end of the fourth quarter of fiscal 2025 (quarter ending September 30, 2025), excluding expenses associated with the retirement of the Company’s former Chairman and CEO.

• Since initiating its strategic restructuring in December 2024, Applied DNA has exited non-core operations and reduced headcount by 39% for a projected 31% reduction in annual payroll expenses as compared to the fiscal year ended September 30, 2024, excluding costs related to the retirement of the Company’s former Chairman and CEO. In addition to the actions reported in this press release, the Company exited its DNA Tagging and Security Products and Services business segment in February 2025 and undertook a workforce reduction of approximately 20% of the then-total headcount, primarily related to employees associated with this segment.

• The Company ended May 31, 2025, with approximately $4.8 million in cash and cash equivalents.

About Applied DNA Sciences

Applied DNA Sciences is a biotechnology company with over 20 years of experience in developing and commercializing polymerase chain reaction (PCR)-based applications for DNA production. Through its majority-owned subsidiary, LineaRx Inc., the Company is commercializing its LineaDNA and LineaIVT platforms to enable the manufacture of the next generation of nucleic acid-based therapies.

About the LineaDNA™ and LineaIVT™ Platforms

The LineaDNA platform is a proprietary, cell-free DNA production system leveraging Applied DNA’s deep expertise in large-scale PCR. Unlike conventional plasmid-based DNA production methods, the LineaDNA platform produces high-fidelity DNA that is free of adventitious sequences, rapidly scalable, and easily amenable to chemical modification. It can generate DNA from 100 base pairs to 20 kilobases in quantities from milligrams to grams under RUO, GLP, and GMP quality grades.

The LineaIVT platform offers a streamlined solution for mRNA production via integration of DNA IVT template manufacturing from the LineaDNA platform with the Company’s proprietary LineaRNAP™ enzyme. The platform’s unique integrated approach bypasses plasmid DNA as a starting material, prevents or reduces double-stranded RNA (dsRNA) contamination, and simplifies mRNA production workflows.

Visit adnas.com for more information. Follow us on X and LinkedIn.

Forward-Looking Statements

The statements made by Applied DNA Sciences in this press release may be “forward-looking” in nature within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. Forward-looking statements describe Applied DNA’s future plans, projections, strategies, and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of Applied DNA. These forward-looking statements are based largely on the Company’s expectations and projections about future events and future trends affecting our business and are subject to risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements, including statements regarding its belief that restructuring will position the company for future growth potential, its goal to position the company for long term-growth and value creation and the potential to achieve that goal, the future success of its LineaDNA™ and LineaIVT™ platforms and future reductions in operating expenses. Actual results could differ materially from those projected due to the Company’s history of net losses, limited financial resources, substantial doubt regarding its ability to continue as a going concern, unknown future ability to continue its listing on the Nasdaq Capital Market, unknown future demand for its biotherapeutics products and services, the unknown amount of revenues and profits that will result from our LineaDNA and/or LineaIVT platforms, the fact that there has never been clinical trial material and/or a commercial drug product produced utilizing the LineaDNA and/or LineaIVT platforms, as well as various other factors detailed from time to time in Applied DNA’s SEC reports and filings, including its Annual Report on Form 10-K filed on December 17, 2024, its Quarterly Reports on Form 10-Q filed on February 13, 2025, and May 15, 2025, and other reports it files with the SEC, which are available at www.sec.gov. Applied DNA undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date hereof or to reflect the occurrence of unanticipated events, unless otherwise required by law.

Applied DNA Sciences Contact:

Investor Relations contact: Sanjay M. Hurry, 917-733-5573, sanjay.hurry@adnas.com
Web: https://investors.adnas.com/

SOURCE: Applied DNA Sciences

View the original press release on ACCESS Newswire

LAS VEGAS, NEVADA / ACCESS Newswire / June 30, 2025 / GPO Plus, Inc. (OTCQB:GPOX), an AI-powered Distributor revolutionizing distribution to gas stations and convenience stores with its innovative technology-driven Direct Store Delivery (DSD) model, is proud to share this shareholder update highlighting key achievements and unveiling strategic initiatives designed to generate recurring revenue and fuel sustainable, long-term growth.

Dear Shareholders,

Wow, we are genuinely thrilled about the incredible momentum and extraordinary achievements here at GPOX! In December, we announced several major initiatives, and I am ecstatic about the progress we are making; our future couldn’t look brighter!

Massive heartfelt thanks go out to our shareholders, investors, partners, vendors, and especially our dedicated team. Your unwavering support and enthusiasm fuel our growth, enabling us to execute our strategic vision and consistently achieve remarkable results.

Here’s why you should be excited:

• GPOX is laser-focused on driving aggressive revenue growth.
  Every strategy and initiative is designed to expand our market reach, enhance profitability, and generate tangible value for our shareholders.

• We have been executing our vision extraordinarily well.
  We consistently surpass internal targets, manage resources effectively, and deliver operational excellence across every aspect of our business.

• We’re poised for continued success.
  Exciting initiatives are underway, and our future holds even greater potential. We’re delighted to have you with us on this journey!

Every initiative we’re working on is engineered to enhance profitability and dramatically amplify shareholder value. We’re not just dreaming big; we’re executing relentlessly!

New Sales Initiatives

• DISTRO+ Cash & Carry:
  As highlighted in our recent press releases, this initiative provides retailers with immediate access to our products, streamlining the sales process, reducing lead times, and strengthening retailer relationships through convenience and reliability.

• Call Centers:
  As previously announced, we’ve launched our call center operations to effectively penetrate new markets and regions that are currently underserved, significantly broadening our geographic and revenue footprint nationally.

• Direct Sales Team:
  Since our announcement, our dedicated sales representatives have been engaging retailers personally, building stronger relationships, enhancing customer loyalty, and driving long-term revenue growth.

• Direct-to-Consumer (DTC):
  Later this year, we will launch dedicated websites for our GPOXBrands, directly connecting with consumers and enhancing our brand visibility and profitability.

Q3 Results – Results speak louder than words

• Gross Revenues: Up around 11% year-to-date, reflecting successful strategic initiatives and significant market penetration.

• Operational Efficiency:Operating expenses have been reduced by nearly 30%, showcasing our financial discipline and operational excellence.

• Margin Improvement:Gross margins improved dramatically from 15% to 28%, reflecting the successful optimization and management of resources.

AI + PRISM+ Integration

Strategically integrating AI across our operations, we’re significantly enhancing human productivity, enabling our talented team to focus on high-impact activities. This innovative approach boosts operational efficiency without having to hire additional team members or reduce employment.

Lubbock Regional Hub Upgrade

• We’ve successfully completed a climate-controlled upgrade to our Lubbock facility, enabling us to expand our product lines and optimize our operations, positioning us for substantial future growth.

• We are now working on setting up the Lubbock DISTRO+ Cash + Carry, scheduled to launch this fall.

Las Vegas Warehouse Expansion

• Warehouse Operations:
  We’re actively recruiting and training a dedicated warehouse team to manage our growing distribution capabilities efficiently.

• DISTRO+ Cash & Carry Launch:
  Our highly anticipated Las Vegas DISTRO+ Cash + Carry operation is set to launch this fall, substantially elevating our local market presence and distribution capabilities.

• Expanded Warehouse Facility:
  We’ve secured additional warehouse space, which will significantly improve logistics, inventory management, and customer service.

Las Vegas Call Center Launch: Phase 1 Initiated

• Experienced Call Center Leadership hired.
  We’ve brought on an experienced leader to drive operational excellence within our call centers and general sales.

• Rapid Team Expansion.
  A proactive growth strategy demonstrating confidence in this channel’s revenue-generating capabilities.

• Phase 2 will add additional seats in a second Las Vegas location.
  Planning is underway to launch a second call center. This will add up to 12 additional positions. Expanding our capacity significantly boosts sales potential and market coverage.

SurgePays Strategic Partnership

We’ve effectively initiated a strategic collaboration with SurgePays (NASDAQ:SURG), significantly enhancing our market penetration and optimizing our sales effectiveness through combined resources and expertise. We announced the desire to build a dedicated outbound sales team for GPOX to bring our high-demand product lines to their retail network.

New Product Categories

We’re actively expanding our product offerings, strategically aligning new, high-demand categories with our distribution model to enhance profitability and market opportunities. This will provide lucrative opportunities that are specifically aligned with our efficient DISTRO+ Cash + Carry b2b business and distribution model.

Las Vegas Field Team: G-Force

• We recently announced the deployment of our GPOXField Operations + Retail Channel Engagement sales team, “G-FORCE” in Las Vegas to drive new retail account growth and deepen market penetration.

• Our dynamic G-Force team is establishing ongoing relationships with local retailers, engaging with them regularly to ensure a strong brand presence, outstanding customer service, and robust revenue growth.

• With the early success, we will likely deploy G-FORCE into other markets as well.

DISTRO+ Wholesale Portal

We’ve launched an efficient and streamlined portal to simplify retailer interactions, significantly enhance ordering processes, and rapidly introduce new products, thereby greatly enhancing operational efficiency.

---

GPOX has shifted decisively from the foundational build-out of its DSD infrastructure to executing a nationwide growth strategy. With a longer-term objective of scaling to over 20,000 retail partners, each generating more than $5,000 per month in sales nationwide.

Once again, thank you for your ongoing support and enthusiasm as we continue to execute these exciting initiatives. Together, we’re building a truly remarkable future!

Best,

Brett H. Pojunis
CEO, GPO Plus, Inc.

---

For more information on GPOX’s growth initiatives, visit GPOPlus.com.

Connect with us on social media to view live video updates, content, and general information about GPOX: https://gpoplus.com/social.

---

About GPOPlus+ (GPOX)
GPOX is an AI-powered Distributor revolutionizing the future of distribution to gas stations and convenience stores with its innovative technology-driven Direct Store Delivery (DSD) model. Our goal is clear and ambitious: “to build the largest nationwide DSD distribution company servicing gas stations, convenience stores, and beyond.” Our technology-driven AI network, featuring strategically placed Regional Hubs and Mini Hubs, is designed to optimize efficiency and maximize reach. Central to our operations is our in-house AI technology platform, PRISM+. Designed to streamline the distribution process, PRISM+ supports efficient delivery, inventory management, data analytics, and overall operational excellence, enabling us to reliably and effectively meet the dynamic needs of our partners. Our mission is to consolidate the fragmented market segment managed by numerous regional vendors. Our dedication to excellence is evident in our product selection process, where we align offerings with consumer demand and partner with top-tier vendors and brands, ensuring our portfolio remains diverse and highly profitable. For more information, please visit www.GPOPlus.com.

---

Information about Forward-Looking Statements

This press release contains “forward-looking statements” that include statements regarding expected financial performance and growth information relating to future events. Forward-looking statements include statements with respect to beliefs, plans, objectives, goals, expectations, anticipations, assumptions, estimates, intentions, and future performance, and involve known and unknown risks, uncertainties and other factors, which may be beyond the control of the Company and its officers and managers, and which may cause actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Forward-looking statements should not be read as a guarantee of future performance or results and will not necessarily be accurate indications of the times at, or by which, that performance or those results will be achieved. Forward-looking statements are based on information available at the time they are made and/or management’s good faith belief as of that time with respect to future events and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in, or suggested by, the forward-looking statements. Important factors that could cause these differences include, but are not limited to; inability to gain or maintain licenses, reliance on unaudited statements, the Company’s need for additional funding, governmental regulation of the cannabis industry, the impact of competitive products and pricing, the demand for the Company’s products, and other risks that are detailed from time-to-time in the Company’s filings with the United States Securities and Exchange Commission. All statements other than statements of historical fact are statements that could be forward-looking statements. You can typically identify these forward-looking statements through use of words such as “may,” “will,” “can” “anticipate,” “assume,” “should,” “indicate,” “would,” “believe,” “contemplate,” “expect,” “seek,” “estimate,” “continue,” “plan,” “point to,” “project,” “predict,” “could,” “intend,” “target,” “potential,” and other similar words and expressions of the future. The Company expresses its expectations, beliefs and projections in good faith and believes that its expectations reflected in these forward-looking statements are based on reasonable assumptions. However, there is no assurance that these expectations, beliefs and projections will prove to have been correct. Such statements reflect the current views of the Company with respect to its operations and future events, and are subject to certain risks, uncertainties and assumptions relating to its proposed operations, including the risk factors set forth herein. Should one or more of these risks or uncertainties materialize or should the underlying assumptions prove incorrect, the Company’s actual results may vary significantly from those intended, anticipated, believed, estimated, expected or planned. In light of these risks, uncertainties and assumptions, any favorable forward-looking events discussed herein might not be realized and occur. The Company has no obligation to update or revise its forward-looking statements, whether as a result of new information, future events or otherwise. For a more detailed description of the risk factors and uncertainties affecting GPO Plus, Inc. GPOX, please refer to the Company’s recent Securities and Exchange Commission filings, which are available at www.sec.gov. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Company Contacts:

GPOX Shareholder Success Team:
Brett H. Pojunis, CEO
Email: ir@gpoplus.com
Shareholder’s Line: 855.935.GPOX (4769)

SOURCE: GPO Plus, Inc.

View the original press release on ACCESS Newswire

As recently announced, initial proof-of-concept results from this ongoing investigator-initiated trial (IIT) show crofelemer reduced the required total parenteral nutrition in the first participating microvillus inclusion disease (MVID) patient by up to 27% and in the first participating short bowel syndrome patient by up to 12.5%

The first two patients in this IIT were taken off crofelemer after 12 weeks of treatment for a period intended to last 30 days, per the study protocol, but were promptly placed back on daily crofelemer treatment because their symptoms worsened

Company strategy: Seek business development partnerships for license to develop and commercialize Jaguar’s intestinal failure products, resulting in non-dilutive funding for Jaguar

SAN FRANCISCO, CA / ACCESS Newswire / June 30, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) family companies Napo Pharmaceuticals (Napo) and Napo Therapeutics today announced that initial proof-of-concept results show that a novel liquid formulation of crofelemer reduced the required total parenteral nutrition (TPN) and supplementary intravenous fluids in a third intestinal failure patient. This is the second pediatric patient with intestinal failure due to the orphan disease short bowel syndrome (SBS-IF) who was treated with crofelemer. To date, three patients with intestinal failure due to SBS-IF or microvillus inclusion disease (MVID) have been treated with crofelemer in this exploratory, single-arm open label non-randomized IIT in Abu Dhabi.

As announced, and as presented April 26, 2025 at the Annual ELITE PED-GI Congress, initial proof-of-concept results from this study show that crofelemer, Jaguar’s novel plant-based anti-secretory prescription drug, reduced the required TPN and supplementary intravenous fluids in the first participating MVID patient by up to 27% and in the first participating SBS-IF patient by up to 12.5%. In addition, this data showed that crofelemer reduced stool volume output and/or frequency of watery stools, and increased urine output – an indicator of improved nutrient oral absorption.

“We’re very pleased to report that the second pediatric SBS-IF patient participating in this IIT exhibited a similar response for TPN reduction, further exemplifying that crofelemer’s paradigm-shifting antisecretory mechanism of action may have the potential to provide a novel therapeutic option to modify disease progression due to the reductions in TPN and associated comorbidities in MVID and SBS-IF patients and improve their quality of life,” said Lisa Conte, Jaguar’s Founder and CEO. “This SBS-IF patient was administered the highest dose of crofelemer provided for in the approved protocol for the IIT, with no resulting safety issues.”

Per the IIT protocol, as announced, the initial pediatric MVID patient participating in the study was taken off crofelemer after 12 weeks of treatment for an intended period of 30 days. However, after just 8 days, the patient’s parents requested reinitiation of crofelemer dosing, as the patient’s symptoms worsened – evidenced by increased stool output and decreased urine output – and the patient was restarted on daily treatment with crofelemer. The initial pediatric SBS-IF patient participating in the study also had crofelemer withdrawn per the protocol after 12 weeks. This patient then exhibited a relapse of symptoms and was put back on daily treatment with crofelemer, and has since been maintaining a significant TPN reduction. Jaguar plans to continue supplying crofelemer to Dr. Mohamad Miqdady, the principal investigator for this IIT, for the patients participating in this study for as long as Dr. Miqdady feels is medically necessary.

Dr. Miqdady has submitted initial proof-of-concept data from the ongoing IIT in Abu Dhabi for all three above-referenced patients to a major international pediatric gastroenterological conference for consideration for presentation.

Jaguar, through Jaguar family companies Napo and Napo Therapeutics, is currently supporting two independent proof-of-concept IITs, and conducting two placebo-controlled Phase 2 studies, of crofelemer in patients with intestinal failure due to MVID and SBS-IF in the United States, European Union, and/or Middle East/North Africa regions.

Completion of Napo’s randomized double-blind, placebo-controlled Phase 2 study of crofelemer in pediatric MVID patients is expected in mid-2026 as planned.

“Our strategy is to seek business development partnerships for license rights for development and commercialization of Jaguar’s intestinal failure products – with the goal of generating non-dilutive funding for Jaguar,” said Conte. “Given the ultrarare nature of MVID, and the groundbreaking initial proof-of-concept results from the ongoing IIT in Abu Dhabi, even a small number of MVID patients showing benefit with crofelemer may allow Napo to explore pathways for expedited regulatory approval.”

Based on the initial findings of the ongoing IIT in Abu Dhabi, crofelemer’s paradigm-shifting antisecretory mechanism of action appears to have the potential to provide a novel therapeutic option to reduce TPN and associated complications, including liver, renal, and cognitive deficits, as well as infections from IV infusion, in patients with intestinal failure due to MVID and short bowel syndrome. The observed groundbreaking TPN reduction is particularly compelling for MVID, an ultrarare pediatric disease characterized by severe diarrhea and malabsorption that requires intensive parenteral support for nutritional and fluid management and for which no approved drug treatments exist, or any potential approach to reduce TPN.

The initial proof-of-concept data in MVID supports crofelemer’s potential inclusion in the European Medicines Agency’s (EMA) PRIME program that may accelerate regulatory approval pathways in the EU for this indication. This data may also support qualification of crofelemer for the FDA’s Breakthrough Therapy program for expedited regulatory approval in the US. Additional proof-of-concept results from IITs are expected throughout 2025 and will provide additional preliminary data on the safety and potential effectiveness of crofelemer for these highly unmet clinical needs. In accordance with the guidelines of specific EU countries, published data from clinical investigations in MVID and SBS-IF could support reimbursed early patient access to crofelemer for these debilitating conditions.

The IIT in Abu Dhabi is being conducted by Dr. Miqdady at Sheikh Khalifa Medical City (SKMC), a flagship tertiary hospital in the United Arab Emirates and the largest teaching medical center in Abu Dhabi. Dr. Miqdady, a recognized leader in pediatric gastroenterology, serves as the Chief of Pediatric Gastroenterology, Hepatology and Nutrition at SKMC. He is an American board-certified pediatric GI, hepatology and nutrition professor at Khalifa University in Abu Dhabi, and also serves as a member of Napo’s Scientific Advisory Board. Dr. Miqdady completed his Fellowship in Pediatric Gastroenterology at Baylor College of Medicine and Texas Children’s Hospital in Houston.

About Crofelemer

Crofelemer is a novel, oral plant-based prescription medicine purified from the red bark sap, also referred to as “dragon’s blood,” of the Croton lechleri tree in the Amazon Rainforest. Napo Pharmaceuticals has established a sustainable harvesting program, under fair trade practices, for crofelemer to ensure a high degree of quality, ecological integrity, and support for indigenous communities.

About the Jaguar Health Family of Companies

Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Jaguar family company Napo Pharmaceuticals focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states. Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan diseases. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar’s Entheogen Therapeutics Initiative(ETI), is focused on developing novel prescription medicines derived from plants for mental health indications.

For more information about:

Jaguar Health, visit https://jaguar.health/

Napo Pharmaceuticals, visit www.napopharma.com Napo Therapeutics, visit napotherapeutics.com Magdalena Biosciences, visit magdalenabiosciences.com

Visit the Make Cancer Less Shitty patient advocacy program on Bluesky, X, Facebook & Instagram

Forward-Looking Statements

Certain statements in this press release constitute “forward-looking statements.” These include statements regarding Jaguar’s expectation that completion of Napo’s Phase 2 study of crofelemer in pediatric MVID patients will occur mid-2026, Jaguar’s expectation that its strategy of seeking business development partnerships for license rights for development and commercialization of Jaguar’s intestinal failure products may support generation of non-dilutive funding for Jaguar, Jaguar’s expectation that even a small number of MVID patients showing benefit with crofelemer may allow Napo to explore pathways for expedited regulatory approval of crofelemer for MVID, Jaguar’s expectation that crofelemer’s mechanism of action may have the potential to provide a novel therapeutic option to reduce TPN and associated complications, including liver, renal, and cognitive deficits, as well as infections from IV infusion, in pediatric MVID and SBS-IF patients, Jaguar’s expectation that proof-of-concept data in MVID may support crofelemer’s potential inclusion in the EMA’s PRIME program for expediated and assisted regulatory approval and in the FDA’s Breakthrough Therapy program for expedited regulatory approval in the US, Jaguar’s expectation that additional proof-of-concept results from IITs will be available throughout 2025, and Jaguar’s expectation that published data from clinical investigations in MVID and SBS-IF could support reimbursed early patient access to crofelemer for MVID and SBS-IF. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “aim,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to several risks, uncertainties, and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar’s control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

Contact:

hello@jaguar.health

Jaguar-JAGX

SOURCE: Jaguar Health, Inc.

View the original press release on ACCESS Newswire

Fueled by Over 13 Million Global Creators, Milestone Reflects Platform Growth, Strategic Positioning, and Accelerating Creator Monetization

NEWPORT BEACH, CA / ACCESS Newswire / June 30, 2025 / Amaze Holdings, Inc. (NYSE American:AMZE) (“Amaze”), a global leader in creator-powered commerce, today announced that its subsidiary, Amaze Software, Inc. (“Amaze Software“) has surpassed 200 million lifetime storefront visits across its platform. This achievement underscores the platform’s scale and influence in the rapidly expanding creator economy and is powered by a global community of over 13 million creators who use Amaze to build and sell products.

As more people turn to creators for entertainment, inspiration, and product discovery, Amaze is enabling those creators to monetize their content, audiences, and ideas through streamlined e-commerce tools. Amaze helps creators design, launch, and sell physical and digital products directly to fans, eliminating barriers between content and commerce.

“Crossing 200 million storefront visits is proof that when creators are given the right tools, they become economic engines,” said Aaron Day, CEO of Amaze Software. “This milestone reflects the shift we’re seeing in global commerce, away from traditional retail and toward community-powered shopping experiences. We’re proud to support over 13 million creators driving this movement forward.”

This milestone comes at a time of sustained growth across both the creator economy and global ecommerce:

• The creator economy is projected to reach $480 billion by 2027, nearly doubling from $250 billion in 2023¹.

• Global creator count is estimated to rise from over 67 million creators globally in 2025 to 107 million by 2030, with monetization pathways like product commerce outpacing sponsorships².

• Global retail ecommerce sales are forecast to reach $6.42 trillion in 2025³, rising to over $7.5 trillion by 2027, with2.77 billion global digital buyers driving the shift⁴.

By aligning with these macroeconomic tailwinds, Amaze is uniquely positioned to scale with the future of creator-led commerce. Through ongoing investments in platform innovation, fulfillment, and strategic partnerships, Amaze is building a future where creators everywhere can launch and grow businesses their fans love.

To learn more about Amaze and how it powers the creator economy, visit www.amaze.co.

¹Source: Goldman Sachs Research, Creator Economy Report, April 2023

²Source: Forbes, How The Creator Economy Is Changing The Future Of Work, citing Goldman Sachs Research, July 2023

³Source: eMarketer, Worldwide Retail Ecommerce Sales Forecast, 2023

⁴Source: SellersCommerce, Global Ecommerce Statistics, 2023

For investor information, please contact IR@amaze.co

For press inquiries, please contact PR@amaze.co

About Amaze:
Amaze Software, Inc. is an end-to-end, creator-powered commerce platform offering tools for seamless product creation, advanced e-commerce solutions, and scalable managed services. By empowering anyone to “sell anything, anywhere,” Amaze enables creators to tell their stories, cultivate deeper audience connections, and generate sustainable income through shoppable, authentic experiences. Discover more at www.amaze.co.

Cautionary Note Regarding Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). These statements relate to future events and developments or to our future operating or financial performance, are subject to risks and uncertainties and are based estimates and assumptions. Forward-looking statements may include, but are not limited to, statements about our strategies, initiatives, growth, revenues, expenditures, the size of our market, our plans and objectives for future operations, and future financial and business performance. These statements can be identified by words such as such as “may,” “might,” “should,” “would,” “could,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “potential” or “continue,” and are based our current expectations and views concerning future events and developments and their potential effects on us.

These statements are subject to known and unknown risks, uncertainties and assumptions that could cause actual results to differ materially from those projected or otherwise implied by the forward-looking statement. These risks include: our ability to execute our plans and strategies; our limited operating history and history of losses; our financial position and need for additional capital; our ability to attract and retain our creator base and expand the range of products available for sale; we may experience difficulties in managing our growth and expenses; we may not keep pace with technological advances; there may be undetected errors or defects in our software or issues related to data computing, processing or storage; our reliance on third parties to provide key services for our business, including cloud hosting, marketing platforms, payment providers and network providers; failure to maintain or enhance our brand; our ability to protect our intellectual property; significant interruptions, delays or outages in services from our platform; significant data breach or disruption of the information technology systems or networks and cyberattacks; risks associated with international operations; general economic and competitive factors affecting our business generally; changes in laws and regulations, including those related to privacy, online liability, consumer protection, and financial services; our dependence on senior management and other key personnel; and our ability to attract, retain and motivate qualified personnel and senior management.

Additional risks and uncertainties that could cause actual outcomes and results to differ materially from those contemplated by the forward-looking statements are included in our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and other future filings and reports that we file with the Securities and Exchange Commission (SEC) from time to time. Given these risks and uncertainties, you should not place undue reliance on these forward-looking statements. Also, these forward-looking statements represent our estimates and assumptions only as of the date of the press release. Unless required by law, we undertake no obligation to update or revise any forward-looking statements to reflect new information or future events or developments.

SOURCE: Amaze Holdings, Inc.

View the original press release on ACCESS Newswire

BOCA RATON, FL / ACCESS Newswire / June 30, 2025 / Newsmax Inc. (NYSE:NMAX) (“Newsmax” or the “Company”) today announced that the Company has officially been added to the U.S. small-cap Russell 2000® Index, effective as of market open on June 30, 2025, as part of FTSE Russell’s annual reconstitution.

The Company’s inclusion in the Russell 2000® Index, as well as the broader Russell 3000® Index, provides Newsmax with increased visibility within the institutional investor community. The Russell indexes are widely used by investment managers and institutional investors, with approximately $10.6 trillion in assets benchmarked against Russell’s U.S. indexes.

Meanwhile, Newsmax continues to expand its reach, having recently secured expanded distribution through Hulu+, which has helped achieve household penetration of approximately 60 million U.S. homes. The Company has also announced international distribution agreements in Israel, Armenia and the Dominican Republic.

Newsmax+, Newsmax’s streaming service via its subscription app, has also seen notable expansion, and is now available on Comcast’s entertainment devices across the U.S., including Xfinity X1, Xfinity Flex, Xumo Stream Box and Xumo TV.

About Newsmax

Newsmax Inc. is listed on the NYSE (NMAX) and operates, through Newsmax Broadcasting LLC, one of the nation’s leading news outlets, the Newsmax channel. The fourth highest-rated network is carried on all major cable stations, as well as a major satellite system. Newsmax’s media properties reach more than 40 million Americans regularly through Newsmax TV, the Newsmax App, its popular website Newsmax.com, and publications such as Newsmax Magazine. Through its social media accounts, Newsmax reaches 20 million combined followers. Reuters Institute says Newsmax is one of the top U.S. news brands and Forbes has called Newsmax “a news powerhouse.”

For more information, please visit Investor Relations | Newsmax Inc.

About FTSE Russell, an LSEG Business

FTSE Russell is a global index leader that provides innovative benchmarking, analytics and data solutions for investors worldwide. FTSE Russell calculates thousands of indexes that measure and benchmark markets and asset classes in more than 70 countries, covering 98% of the investable market globally. FTSE Russell index expertise and products are used extensively by institutional and retail investors globally. Approximately $18.1 trillion is benchmarked to FTSE Russell indexes. Leading asset owners, asset managers, ETF providers and investment banks choose FTSE Russell indexes to benchmark their investment performance and create ETFs, structured products and index-based derivatives. A core set of universal principles guides FTSE Russell index design and management: a transparent rules-based methodology is informed by independent committees of leading market participants. FTSE Russell is focused on applying the highest industry standards in index design and governance and embraces the IOSCO Principles. FTSE Russell is also focused on index innovation and customer partnerships as it seeks to enhance the breadth, depth and reach of its offering.

FTSE Russell is wholly owned by London Stock Exchange Group.

For more information, visit FTSE Russell.

Forward-Looking Statements

This communication contains forward-looking statements. From time to time, we or our representatives may make forward-looking statements orally or in writing. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Forward-looking statements can be identified by those that are not historical in nature. The forward-looking statements discussed in this communication and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties and assumptions about us. Newsmax does not guarantee future results, performance or achievements. Moreover, neither we nor any other person assumes responsibility for the accuracy or completeness of any of these forward-looking statements. Forward-looking statements should not be relied upon as predictions of future events. We are under no duty to update any of these forward-looking statements after the date of this communication to conform our prior statements to actual results or revised expectations, and we do not intend to do so. Factors that may cause actual results to differ materially from current expectations include various factors, including but not limited to our ability to change the direction of Newsmax, our ability to keep pace with new technology and changing market needs, the competitive environment of our business changes in domestic and global general economic and macro-economic conditions and/or uncertainties and factors set forth in the sections entitled “Risk Factors” in Newsmax’s Annual Report on Form 10-K for the twelve months ended December 31, 2024, Newsmax’s Quarterly Report on Form 10-Q for the three months ended March 31, 2025, and other filings Newsmax makes with the Securities and Exchange Commission. Nothing in this communication should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. Undue reliance should not be placed on forward-looking statements in this communication, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein.

Investor Contacts

Newsmax Investor Relations
ir@newsmax.com

SOURCE: Newsmax Inc.

View the original press release on ACCESS Newswire

Hinson brings a proven track record of driving growth and innovation in sales organizations

BOCA RATON, FL / ACCESS Newswire / June 30, 2025 / Greenlane Holdings, Inc. (“Greenlane” or the “Company”) (Nasdaq:GNLN), one of the premier global sellers of premium cannabis accessories, child-resistant packaging, and specialty vaporization products, today announced the appointment of Mike Hinson as the Company’s Executive Vice President of Sales. Hinson will be responsible for revenue optimization, sales strategies, business development and emerging growth opportunities. Hinson brings more than two decades of experience leading high-performing sales teams and driving substantial revenue growth for top-tier companies.

Mike Hinson, Executive Vice President of Sales, Greenlane

Prior to Greenlane, Hinson served as Senior Vice President of Sales at Besmartee, a digital mortgage platform designed to streamline and automate the loan process in the mortgage industry. While at Besmartee, Hinson was responsible for developing and executing the company’s sales strategy, managing a team of regional sales managers and account executives, and identifying new business opportunities to drive revenue growth. He has also held leadership roles at AudienceView, RealPage, Inc., and Paciolan, where he demonstrated his ability to build and manage high-performing sales teams, implement effective sales strategies, and forge strong relationships with key industry players.

Hinson holds a Bachelor of Business Administration degree from James Madison University.

“We are excited to welcome Mike as our new Executive Vice-President of Sales,” said Barbara Sher, Chief Executive Officer for Greenlane. “Through his experience in creating, developing, and supporting high-performance sales organizations, Mike will collaborate with our teams to enhance sales and marketing initiatives throughout the entire organization. He is well suited to excel in expanding our branded product lines, enhancing our sales strategies and maximizing our revenue opportunities as we expand our product footprint in the cannabis and wellness industry.”

Commenting on his appointment, Hinson said, “I look forward to working closely with our sales, marketing and distribution teams in support of our partners and customers. I am determined that we will have a laser sharp focus on our product and sales goals and will employ best practices to organize our teams to maximize efficiency and productivity. I have a track record of exceeding expectations for my own personal sales efforts and for the teams I have led, and I look forward to bringing that expertise to help Greenlane exceed its goals.”

About Greenlane Holdings, Inc.

Founded in 2005, Greenlane is a premier global platform for the development and distribution of premium smoking accessories, vape devices, and lifestyle products to thousands of producers, processors, specialty retailers, smoke shops, convenience stores, and retail consumers. We operate as a powerful family of brands, third-party brand accelerator, and an omnichannel distribution platform.

We proudly offer our own diverse brand portfolio and our exclusively licensed Marley Natural and K.Haring branded products. We also offer a carefully curated set of third-party products through our direct sales channels and our proprietary, owned and operated e-commerce platforms which include Vapor.com, PuffItUp.com, HigherStandards.com, Wholesale.Greenlane.com and MarleyNaturalShop.com.

For additional information, please visit: https://investor.gnln.com. For additional information, please visit: https://gnln.com/.

Investor Contact:

IR@greenlane.com

or

TraDigital IR
Kevin McGrath
+1-646-418-7002
kevin@tradigitalir.com

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 concerning Greenlane and other matters. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “could,” “intends,” “targets,” “projects,” “contemplates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these terms or other similar expressions. The forward-looking statements in this press release are only predictions. Greenlane has based these forward-looking statements largely on its current expectations and projections about future events and financial trends that it believes may affect its business, financial condition and results of operations. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. You should carefully consider the risks and uncertainties that affect our business, including those described in our filings with the Securities and Exchange Commission (“SEC”), including under the caption “Risk Factors” in Greenlane’s Annual Report on Form 10-K filed for the year ended December 31, 2023 and the Company’s other filings with the SEC, which can be obtained on the SEC website at www.sec.gov. These forward-lookingstatements speak only as of the date of this communication. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements, whether as a result of any new information, future events or otherwise. You are advised, however, to consult any further disclosures we make on related subjects in our public announcements and filings with the SEC.

SOURCE: Greenlane Holdings, Inc.

View the original press release on ACCESS Newswire

New Integration Delivers Real-Time Fan Insights and AI-Powered Segmentation to Drive Growth in the Rapidly Expanding Creator Economy

NEWPORT BEACH, CA / ACCESS Newswire / June 30, 2025 /  Amaze Holdings, Inc. (NYSE American:AMZE) (“Amaze”), a global leader in creator-powered commerce, today announced that its subsidiary, Amaze Software, Inc. (“Amaze Software”), has partnered with VisitIQ, the leading marketing intelligence platform for real-time fan and audience modeling and activation.

This strategic collaboration unlocks powerful new capabilities for Amaze to analyze, visualize, and activate first-party fan and creator data across its fast-growing platform. VisitIQ’s proprietary fan heat mapping, behavioral modeling, and AI-powered trend analysis will enable Amaze to turn deep audience insights into smarter marketing, more comprehensive creator support, and product innovation.

Key Benefits of the Integration:

• Precision Targeting: Leveraging VisitIQ’s fan heat maps to visualize overlaps across creators, categories, and regions-fueling sharper lifecycle marketing, paid media targeting, and partnership strategies.

• Smarter Segmentation: AI-powered modeling surfaces behavioral connections among both fans and creators-allowing Amaze to uncover trends, spot rising talent, and shape new monetization strategies based on data, not guesswork.

• Lookalike Growth: By identifying high-intent audiences that mirror top performers, Amaze can accelerate the acquisition of new fans for creators and surface similar creators primed for success.

“This data gives us a 360-degree view of our ecosystem,” said Aaron Day, CEO of Amaze Software. “Not only can we better understand where fan engagement is happening and what’s driving it-we can also see how creators are building momentum, where growth is emerging, and how we can support and scale that success. VisitIQ is helping us turn insight into action at every level.”

Beyond audience insights, VisitIQ’s platform helps Amaze analyze creator performance across launch cadence, category, pricing, and geography, transforming how the company prioritizes product innovation, marketplace expansion, and brand matchmaking. These intelligence layers are being integrated directly into internal dashboards, powering real-time decisions and predictive strategy.

“Amaze has built one of the most robust and dynamic ecosystems in creator commerce,” said Vern Hanzlik, CEO of VisitIQ. “By combining our real-time AI segmentation tools with their platform intelligence, we’re enabling the kind of insight that makes creator-powered commerce not just scalable, but also strategic and profitable.”

With millions of fans and thousands of successful storefronts, Amaze is increasingly focused on lifecycle intelligence as a key growth lever. This partnership marks a pivotal step in its 2025 roadmap-fueling smarter audience acquisition, optimizing creator support, and accelerating brand partnerships.

For investor information, please contact IR@amaze.co

or press inquiries, please contact PR@amaze.co

About Amaze:
Amaze Software, Inc. is an end-to-end, creator-powered commerce platform offering tools for seamless product creation, advanced e-commerce solutions, and scalable managed services. By empowering anyone to “sell anything, anywhere,” Amaze enables creators to tell their stories, cultivate deeper audience connections, and generate sustainable income through shoppable, authentic experiences. Discover more at www.amaze.co.

About VisitIQ:
VisitIQ™ is a marketing intelligence and activation engine that leverages the power of AI to identify prospects most likely to convert. VisitIQ™ analyzes billions of real-time intelligence signals like digital footprint metrics, streaming activity, ad viewing, buying intent signals and geolocational patterns to identify marketing targets and create ideal customer profiles (ICPs)-then activate those targets to any marketing campaign.

VisitIQ™ allows marketers to curb rising campaign costs and overcome restrictive intelligence monopolies by personalizing marketing campaigns, driving sales conversions and increasing the ROI of digital marketing initiatives-across all marketing channels.

Cautionary Note Regarding Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). These statements relate to future events and developments or to our future operating or financial performance, are subject to risks and uncertainties and are based estimates and assumptions. Forward-looking statements may include, but are not limited to, statements about our strategies, initiatives, growth, revenues, expenditures, our plans and objectives for future operations, and future financial and business performance. These statements can be identified by words such as such as “may,” “might,” “should,” “would,” “could,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “potential” or “continue,” and are based our current expectations and views concerning future events and developments and their potential effects on us.

These statements are subject to known and unknown risks, uncertainties and assumptions that could cause actual results to differ materially from those projected or otherwise implied by the forward-looking statement. These risks include: our ability to execute our plans and strategies; our limited operating history and history of losses; our financial position and need for additional capital; our ability to attract and retain our creator base and expand the range of products available for sale; we may experience difficulties in managing our growth and expenses; we may not keep pace with technological advances; there may be undetected errors or defects in our software or issues related to data computing, processing or storage; our reliance on third parties to provide key services for our business, including cloud hosting, marketing platforms, payment providers and network providers; failure to maintain or enhance our brand; our ability to protect our intellectual property; significant interruptions, delays or outages in services from our platform; significant data breach or disruption of the information technology systems or networks and cyberattacks; risks associated with international operations; general economic and competitive factors affecting our business generally; changes in laws and regulations, including those related to privacy, online liability, consumer protection, and financial services; our dependence on senior management and other key personnel; and our ability to attract, retain and motivate qualified personnel and senior management.

Additional risks and uncertainties that could cause actual outcomes and results to differ materially from those contemplated by the forward-looking statements are included in our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and other future filings and reports that we file with the Securities and Exchange Commission (SEC) from time to time. Given these risks and uncertainties, you should not place undue reliance on these forward-looking statements. Also, these forward-looking statements represent our estimates and assumptions only as of the date of the press release. Unless required by law, we undertake no obligation to update or revise any forward-looking statements to reflect new information or future events or developments.

SOURCE: Amaze Holdings, Inc.

View the original press release on ACCESS Newswire

Expo Contratista 2025, James Hardie will showcase its latest products and technologies

DALLAS, TX / ACCESS Newswire / June 30, 2025 / James Hardie Building Products Inc. (James Hardie), a subsidiary of James Hardie Industries plc (ASX:JHX)(NYSE:JHX) and the #1 brand of siding in North America*, proudly announces its role as the Title Sponsor of the National Hispanic Construction Tradeshow and Convention, Expo Contratista 2025. This premier industry event will be held October 24-25, 2025 at the Irving Convention Center in Irving, Texas, bringing together Hispanic and Latino contractors, builders, and industry professionals from across the country.

Expo Contratista is the largest tradeshow and convention dedicated to Hispanic and Latino construction professionals, providing a platform for networking, education, and innovation. As the Title Sponsor, James Hardie demonstrates its commitment to supporting the Hispanic and Latino contracting community by promoting industry growth, professional development, and business success.

“We are honored to partner with Expo Contratista 2025 as the Title Sponsor,” said Heather Jones, Marketing Director at James Hardie Building Products Inc. “The Hispanic and Latino contracting community is a vital force in the construction industry, and we are committed to empowering professionals with innovative, durable, and sustainable building solutions that drive long-term success.”

During Expo Contratista 2025, James Hardie will showcase its latest products and technologies, offering attendees the opportunity to connect with industry experts, participate in hands-on demonstrations, and explore solutions designed to enhance jobsite efficiency and performance.

“James Hardie’s support highlights the importance of fostering meaningful connections within the Hispanic and Latino contractor community,” said Sergio Terreros, Event Organizer at Expo Contratista. “Their leadership in the industry aligns with our mission to provide valuable opportunities for education, networking, and business growth.”

For more information about Expo Contratista 2025 and James Hardie’s participation, visit www.ExpoContratista.com.

James Hardie Building Products Inc.

James Hardie truly represents What The Best Are Made Of™. As the #1 brand of siding in North America*, James Hardie offers exterior solutions and accessories for every style. Hardie® products deliver resilient beauty and endless design possibilities, with trusted protection and low maintenance. Hardie® products are noncombustible** and stand up to weather while empowering homeowners and building professionals to achieve the home of their dreams. James Hardie operates with an inclusive company culture and an unwavering commitment to Zero Harm. The company proudly employs a diverse workforce of over 3,700 employees in North America.

For more information and media resources, visit JamesHardie.com and JamesHardie.com/all-about-james-hardie/media-resources. For investor information, please visit ir.jameshardie.com.au.

* Based on Freedonia 2022 Global Siding (Cladding) demand estimates and James Hardie sales in North America.

**Hardie® siding complies with ASTM E136 as a noncombustible cladding. Noncombustible siding, when combined with other fire mitigation measures, can help harden a home against external fire.

Connect with James Hardie on social media:
LinkedIn
Instagram
Facebook
X (formerly Twitter)

Media Contact:

James Hardie
jameshardieuspr@webershandwick.com

Investor Contact:
Joe Ahlersmeyer, CFA
Vice President, Investor Relations
investors@jameshardie.com

About Expo Contratista

Expo Contratista stands as the nation’s leading Hispanic construction trade show, dedicated to connecting contractors and construction workers. With a mission to empower the Hispanic market with the knowledge to network and grow businesses in the industry, Expo Contratista continues to be a catalyst for diversity, collaboration, and innovation.

SOURCE: Expo Contratista

View the original press release on ACCESS Newswire